You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Geron is a commercial-stage ...

After an eight-month delay, on 23 January, the US Food and Drug Administration (FDA) approved the first human trials of embryonic stem (hES) cells, a surprise decision that came on the eve of ...

Barclays analyst Peter Lawson lowered the firm’s price target on Geron (GERN) to $4 from $9 and keeps an Overweight rating on the shares post the Q4 report. The firm updated its model to reflect ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal ...

John Scarlett; Chairman of the Board, President, Chief Executive Officer; Geron Corp Jim Ziegler; Executive Vice President, Chief Commercial Officer; Geron Corp Joseph Eid; Executive Vice ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported ...